• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

含阿拉伯半乳聚糖、透明质酸和海藻糖的人工泪液在干眼症患者中的真实世界治疗效果

Real-World Treatment Outcomes of an Artificial Tear Containing Arabinogalactan, Hyaluronic Acid and Trehalose Among Subjects with Dry Eye.

作者信息

Bedei Andrea, Rocha Cabrera Pedro, Oliveira Luis, Castellini Laura, De Grazia Giulia, Remiddi Stefano

机构信息

Ophthalmology Department Casa di Cura San Camillo, Forte dei Marmi, Italy.

Ophthalmology Department Hospital San Juan de Dios Tenerife, Santa Cruz de Tenerife, Spain.

出版信息

Clin Ophthalmol. 2025 Jan 7;19:83-91. doi: 10.2147/OPTH.S480668. eCollection 2025.

DOI:10.2147/OPTH.S480668
PMID:39801568
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11724676/
Abstract

PURPOSE

To assess the efficacy, adherence, and tolerability of a new artificial tear based on arabinogalactan, hyaluronic acid, and trehalose in a population with dry eye disease (DED).

METHODS

A retrospective, real-world, post-marketing study identified 96 adult patients (aged 18-80 years) with signs and symptoms of dry eye. These patients received fixed combination therapy with eye drops containing arabinogalactan, hyaluronic acid, and trehalose at various dosing schedules. The data for this study were collected from April 2022 to June 2023. Patients underwent evaluation at baseline (T0) and after a follow-up period of two-three months (T1) using a patient-reported questionnaire.

RESULTS

In 96 adult patients (71 women and 25 men) with dry eye due to various conditions, the results indicated a 98% positive response to therapy. This response included improvements in vision (13%), comfort (39%), redness (13%), itching (16%), photophobia (4%), and tearing (14%). Additionally, 61% of the patients experienced 1-2 hours of comfort following instillation.

CONCLUSION

This real-life post-marketing study demonstrated clinical improvement of signs and symptoms in patients with dry eye disease using a new artificial tear medical device based on arabinogalactan, hyaluronic acid, and trehalose.

摘要

目的

评估一种基于阿拉伯半乳聚糖、透明质酸和海藻糖的新型人工泪液在干眼症（DED）患者中的疗效、依从性和耐受性。

方法

一项回顾性、真实世界的上市后研究纳入了96例有干眼体征和症状的成年患者（年龄18 - 80岁）。这些患者接受了含有阿拉伯半乳聚糖、透明质酸和海藻糖的滴眼液的固定联合治疗，给药方案各不相同。本研究的数据收集于2022年4月至2023年6月。患者在基线（T0）以及两到三个月的随访期后（T1）使用患者报告问卷进行评估。

结果

在96例因各种情况导致干眼的成年患者（71例女性和25例男性）中，结果显示治疗的阳性反应率为98%。这种反应包括视力改善（13%）、舒适度改善（39%）、眼红改善（13%）、瘙痒改善（16%）、畏光改善（4%）和流泪改善（14%）。此外，61%的患者在滴药后有1 - 2小时的舒适感。

结论

这项真实生活的上市后研究表明，使用一种基于阿拉伯半乳聚糖、透明质酸和海藻糖的新型人工泪液医疗设备可使干眼症患者的体征和症状得到临床改善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4770/11724676/2b92ebd28f8a/OPTH-19-83-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4770/11724676/3b9bb2242d73/OPTH-19-83-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4770/11724676/360991944339/OPTH-19-83-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4770/11724676/a52614a23232/OPTH-19-83-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4770/11724676/9e733168dc27/OPTH-19-83-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4770/11724676/b7abd02f477a/OPTH-19-83-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4770/11724676/2b92ebd28f8a/OPTH-19-83-g0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4770/11724676/3b9bb2242d73/OPTH-19-83-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4770/11724676/360991944339/OPTH-19-83-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4770/11724676/a52614a23232/OPTH-19-83-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4770/11724676/9e733168dc27/OPTH-19-83-g0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4770/11724676/b7abd02f477a/OPTH-19-83-g0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4770/11724676/2b92ebd28f8a/OPTH-19-83-g0006.jpg

相似文献

1
Real-World Treatment Outcomes of an Artificial Tear Containing Arabinogalactan, Hyaluronic Acid and Trehalose Among Subjects with Dry Eye.含阿拉伯半乳聚糖、透明质酸和海藻糖的人工泪液在干眼症患者中的真实世界治疗效果
Clin Ophthalmol. 2025 Jan 7;19:83-91. doi: 10.2147/OPTH.S480668. eCollection 2025.
2
Improving ocular surface comfort in contact lens wearers.改善佩戴隐形眼镜者的眼表面舒适度。
Cont Lens Anterior Eye. 2022 Jun;45(3):101544. doi: 10.1016/j.clae.2021.101544. Epub 2021 Nov 25.
3
Efficacy of artificial tears containing trehalose and hyaluronic acid for dry eye disease in women aged 42-54 versus ≥ 55 years.含海藻糖和透明质酸的人工泪液治疗 42-54 岁与≥55 岁女性干眼症的疗效。
Cont Lens Anterior Eye. 2023 Aug;46(4):101845. doi: 10.1016/j.clae.2023.101845. Epub 2023 Apr 26.
4
Tear Film Stabilization and Symptom Improvement in Dry Eye Disease: The Role of Hyaluronic Acid and Trehalose Eyedrops versus Carmellose Sodium.干眼疾病中泪膜稳定性及症状改善：透明质酸和海藻糖滴眼液与羧甲基纤维素钠滴眼液的作用比较
J Clin Med. 2023 Oct 20;12(20):6647. doi: 10.3390/jcm12206647.
5
Successful management of dry eye disease with a new eye drop formulation combining hyaluronic acid, trehalose, and N-acetyl-aspartyl-glutamic acid (NAAGA).成功管理干眼症，使用一种新的滴眼液配方，结合透明质酸、海藻糖和 N-乙酰天冬氨酸谷氨酸（NAAGA）。
J Fr Ophtalmol. 2024 Sep;47(7):104169. doi: 10.1016/j.jfo.2024.104169. Epub 2024 Jun 4.
6
A Prospective, Crossover, Randomized, Double-Blind Clinical Study Comparing the Effectiveness and Ocular Comfort of 0.1% Hyaluronic Acid and 0.3% Hyaluronic Acid in Patients With Dry Eye Disease.一项前瞻性、交叉、随机、双盲临床研究，比较0.1%透明质酸和0.3%透明质酸对干眼症患者的有效性和眼部舒适度。
Clin Ophthalmol. 2025 Feb 6;19:407-416. doi: 10.2147/OPTH.S489669. eCollection 2025.
7
Comparison of efficacy of trehalose-based eye drops versus topical 0.1% Hyaluronic Acid for management of clinically significant dry eye using non-invasive investigational modalities.使用非侵入性研究方法比较基于海藻糖的眼药水与局部使用0.1%透明质酸治疗临床上显著干眼症的疗效。
Int Ophthalmol. 2021 Oct;41(10):3349-3359. doi: 10.1007/s10792-021-01897-9. Epub 2021 May 27.
8
A randomized, controlled study of the efficacy and safety of a new eyedrop formulation for moderate to severe dry eye syndrome.一项关于一种用于中重度干眼症综合征的新型眼药水制剂疗效与安全性的随机对照研究。
Eur J Ophthalmol. 2017 Jan 19;27(1):1-9. doi: 10.5301/ejo.5000836. Epub 2016 Jul 20.
9
A Preservative-Free Combination of Sodium Hyaluronate and Trehalose Improves Dry Eye Signs and Symptoms and Increases Patient Satisfaction in Real-Life Settings: The TEARS Study.透明质酸钠和海藻糖的无防腐剂组合可改善干眼症状和体征，并提高现实生活环境中患者的满意度：TEARS研究。
Ophthalmol Ther. 2024 Dec;13(12):3123-3134. doi: 10.1007/s40123-024-01044-4. Epub 2024 Oct 21.
10
Effect of Hyaluronic Acid/Trehalose in Two Different Formulations on Signs and Symptoms in Patients with Moderate to Severe Dry Eye Disease.两种不同制剂的透明质酸/海藻糖对中重度干眼症患者体征和症状的影响。
J Ophthalmol. 2018 Aug 1;2018:4691417. doi: 10.1155/2018/4691417. eCollection 2018.

本文引用的文献

1
Post-market surveillance of medical devices: A review.医疗器械上市后监测：综述。
Technol Health Care. 2022;30(6):1315-1329. doi: 10.3233/THC-220284.
2
Synergistic Properties of Arabinogalactan (AG) and Hyaluronic Acid (HA) Sodium Salt Mixtures.阿拉伯半乳聚糖（AG）和透明质酸钠（HA）混合物的协同特性。
Molecules. 2021 Nov 29;26(23):7246. doi: 10.3390/molecules26237246.
3
In vitro amoebicidal effects of arabinogalactan-based ophthalmic solution.基于阿拉伯半乳聚糖的眼科溶液的体外杀阿米巴效果。
Int J Parasitol Drugs Drug Resist. 2021 Aug;16:9-16. doi: 10.1016/j.ijpddr.2021.04.005. Epub 2021 Apr 20.
4
A Meta-Analysis of the Efficacy of Hyaluronic Acid Eye Drops for the Treatment of Dry Eye Syndrome.透明质酸钠滴眼液治疗干眼症疗效的Meta分析
Int J Environ Res Public Health. 2021 Mar 1;18(5):2383. doi: 10.3390/ijerph18052383.
5
Arabinogalactan and hyaluronic acid in ophthalmic solution: Experimental effect on xanthine oxidoreductase complex as key player in ocular inflammation (in vitro study).眼用溶液中的阿拉伯半乳糖聚糖和透明质酸：作为眼内炎症关键因素黄嘌呤氧化还原酶复合物的实验作用（体外研究）。
Exp Eye Res. 2020 Jul;196:108058. doi: 10.1016/j.exer.2020.108058. Epub 2020 May 4.
6
Trehalose augments autophagy to mitigate stress induced inflammation in human corneal cells.海藻糖通过增强自噬来减轻人眼角膜细胞应激诱导的炎症。
Ocul Surf. 2019 Oct;17(4):699-713. doi: 10.1016/j.jtos.2019.08.004. Epub 2019 Aug 11.
7
Severity, therapeutic, and activity tear biomarkers in dry eye disease: An analysis from a phase III clinical trial.干燥性眼疾的严重程度、治疗和活动性泪液生物标志物：来自 III 期临床试验的分析。
Ocul Surf. 2018 Jul;16(3):368-376. doi: 10.1016/j.jtos.2018.05.001. Epub 2018 May 14.
8
Clinical implications of mast cell involvement in allergic conjunctivitis.肥大细胞参与变应性结膜炎的临床意义。
Allergy. 2018 Mar;73(3):528-539. doi: 10.1111/all.13334. Epub 2017 Nov 20.
9
TFOS DEWS II Diagnostic Methodology report.TFOS DEWS II 诊断方法学报告。
Ocul Surf. 2017 Jul;15(3):539-574. doi: 10.1016/j.jtos.2017.05.001. Epub 2017 Jul 20.
10
TFOS DEWS II Sex, Gender, and Hormones Report.TFOS DEWS II 性、性别与激素报告
Ocul Surf. 2017 Jul;15(3):284-333. doi: 10.1016/j.jtos.2017.04.001. Epub 2017 Jul 20.